Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PTGER3 | P43115 | 15/20 | 0.80 |
| ▸ | PTGER4 | P35408 | 15/20 | 0.80 |
| ▸ | PTGER2 | P43116 | 15/20 | 0.80 |
| ▸ | PTGER1 | P34995 | 11/20 | 0.80 |
| ▸ | PTGDR | Q13258 | 1/20 | 0.53 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.52 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.52 |
| ▸ | PKM | P14618 | 1/20 | 0.52 |
| ▸ | LMNA | P02545 | 1/20 | 0.47 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.46 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.46 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL16038777 | 1.00 | PTGER3 (0.80) | PTGER3PTGER4PTGER2PTGER1PTGDR | |
| SCHEMBL16070265 | 1.00 | PTGER3 (0.80) | PTGER3PTGER4PTGER2PTGER1PTGDR | |
| SCHEMBL7798336 | 0.85 | PTGER3 (1.00) | PTGER3PTGER4PTGER2PTGER1PTGDR | |
| SCHEMBL7798340 | 0.85 | PTGER3 (1.00) | PTGER3PTGER4PTGER2PTGER1PTGDR | |
| SCHEMBL3114346 | 0.84 | PTGER4 (0.74) | PTGER3PTGER4PTGER2PTGER1PTGDR | |
| SCHEMBL7805984 | 0.84 | PTGER3 (0.60) | PTGER3PTGER4PTGER2PTGER1PTGDR | |
| SCHEMBL7805980 | 0.84 | PTGER3 (0.60) | PTGER3PTGER4PTGER2PTGER1PTGDR | |
| SCHEMBL3403036 | 0.84 | PTGER4 (0.75) | PTGER3PTGER4PTGER2PTGER1KDM4E | |
| SCHEMBL3403038 | 0.84 | PTGER4 (0.75) | PTGER3PTGER4PTGER2PTGER1KDM4E | |
| SCHEMBL7798442 | 0.84 | PTGER2 (0.79) | PTGER3PTGER4PTGER2PTGER1PTGDR |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-9713615-B2 | Tetrahydroisoquinolin-2-yl-(quinazolin-4-yl)methanone compounds | REXAHN PHARMACEUTICALS, INC. (US) | 2017-07-25 | — | — | US | disclosed |
| US-20160136166-A1 | TETRAHYDROISOQUINOLIN-2-YL-(QUINAZOLIN-4-YL)METHANONE COMPOUNDS | Ocuphire Pharma, Inc. | 2016-05-19 | — | — | US | disclosed |
| EP-2970203-A1 | TETRAHYDROISOQUINOLIN-2-YL-(QUINAZOLIN-4-YL) METHANONE COMPOUNDS AS CANCER CELL GROWTH INHIBITORS | Rexahn Pharmaceuticals, Inc. (US) | 2016-01-20 | — | — | EP | disclosed |
| US-9193707-B2 | Tetrahydroisoquinolin-2-yl-(quinazolin-4-yl)methanone compounds | REXAHN PHARMACEUTICALS, INC. (US) | 2015-11-24 | — | — | US | disclosed |
| WO-2014143960-A1 | TETRAHYDROISOQUINOLIN-2-YL-(QUINAZOLIN-4-YL) METHANONE COMPOUNDS AS CANCER CELL GROWTH INHIBITORS | REXAHN PHARMACEUTICALS, INC. (US) | 2014-09-18 | — | — | WO | disclosed |
| US-20140275129-A1 | TETRAHYDROISOQUINOLIN-2-YL-(QUINAZOLIN-4-YL)METHANONE COMPOUNDS | REXAHN PHARMACEUTICALS, INC. (US) | 2014-09-18 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20140275129-A1 | TETRAHYDROISOQUINOLIN-2-YL-(QUINAZOLIN-4-YL)METHANONE COMPOUNDS | HRAS, RECQL, CDK4 | PTGER3 1810/4885PTGER4 1493/4885PTGER2 1254/4885 |
| US-20160136166-A1 | TETRAHYDROISOQUINOLIN-2-YL-(QUINAZOLIN-4-YL)METHANONE COMPOUNDS | HRAS, RECQL, CDK4 | PTGER3 1810/4885PTGER4 1493/4885PTGER2 1254/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.